A Conversation with Crown Bioscience's Alex Slater
In today's rapidly advancing world of drug discovery and oncology research, a robust partnership between clients and contract research organizations (CROs) is vital for success. We recently sat down with Alex Slater, the Senior Vice President of Commercial at Crown Bioscience, to gain insights into the evolving world of CROs and what clients should look for in their search for a perfect CRO match. Here are some of the key takeaways from our enlightening conversation.
Easing Communication for Successful Partnerships
Slater identified effective, efficient, and clear communication as one of the most critical characteristics a CRO must possess. The initial interaction between the client and the CRO sets the stage for the collaboration, establishing a sense of understanding, confidence, and mutual respect. It's crucial for clients to feel that a CRO understands their needs and can offer feedback based on experience and expertise.
Quality Standards and Problem-solving Approach
Slater asserts that maintaining top-notch quality is a given in this industry. Apart from delivering exceptional quality, CROs should also have a rapid, pragmatic way of handling potential issues. Clients need assurance that problems will be promptly addressed, not swept under the carpet. At the same time, setting clear expectations and being transparent about challenges is critical to maintaining a positive client relationship.
Competition Drives Innovation and Quality
Having strong competition in the field not only offers clients a choice; it also pushes CROs to constantly look inward and improve their offerings. Competition fosters differentiation and improvements in everything from science to customer service.
Emerging Trends in Oncology Research
Slater revealed his enthusiasm about the rapidly evolving landscape of oncology research. With new modalities and approaches emerging, he believes that innovative techniques like liquid biopsies and personalised medicine will become more prevalent. Advancements in technology and our understanding of cancer promise exciting times ahead.
The Contribution of Technology in Oncology
Artificial Intelligence (AI) and quantum computing are set to transform oncology research. According to Slater, technology will enable us to find new targets and provide solutions for previously undruggable targets. The increase in computing power and the advent of technologies like AI will help us handle and make sense of the abundant data generated in drug discovery.
Conclusion: A Call for Deeper Conversations and Lasting Partnerships
Slater encourages openness and broader discussions between clients and CROs. He believes that sharing challenges and understanding goals can lead to bespoke, effective solutions. Likewise, success in this evolving industry involves creative and innovative thinking, and most of all, continuous conversations that foster understanding and mutual growth.As we continue to explore the landscape of oncology research and drug discovery, we invite you to join us at the forefront of this exciting journey. Stay tuned for more illuminating discussions with industry leaders and innovators on our podcast, CrownCast.
